PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
October 12, 2023 12:30 ET
|
PMV Pharmaceuticals, Inc.
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
October 11, 2023 12:00 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 20, 2023 16:05 ET
|
PMV Pharmaceuticals, Inc.
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a...
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 09, 2023 08:00 ET
|
PMV Pharmaceuticals, Inc.
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; updated...
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
June 06, 2023 16:01 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
May 10, 2023 08:00 ET
|
PMV Pharmaceuticals, Inc.
Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation;...
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
March 01, 2023 08:00 ET
|
PMV Pharmaceuticals, Inc.
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV...
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
February 28, 2023 16:05 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 08, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation ...